"rationale","name","label","uuid:ID","instanceType","description","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","","10962340-9b1e-427f-b6d7-a29ed392b844","StudyDesign","The main design for the study","StudyDesign_1"
